Literature DB >> 11100516

[Neurogenic voiding disorders. Current status of diagnosis and therapy].

B Schürch1.   

Abstract

Treatment of the neurogenic voiding disorders which occur after spinal cord injury represents one of the most important challenges of rehabilitation. Inadequate management of neurogenic voiding disorders, especially of urinary incontinence, results in impaired quality of life. Moreover, inadequately treated neurogenic voiding disorders may result in medium and long-term renal complications and even death. Treatment of neurogenic disorders, whatever their origin (spinal cord injury, multiple sclerosis, Parkinson's disease), must take into account the gravity of the neurological disease, the potential risks for the upper urinary tract and the expected quality of life. Therefore, each patient must be considered as a separate entity and treated individually. Recent progress in the comprehension of the neurophysiology of the lower urinary tract and the neurophysiopathology of the neurogenic voiding disorders has been followed by the development of new diagnostic and therapeutic tools aimed at improving the patients' health and quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 11100516

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

Review 1.  [Bladder dysfunction due to spinal cord compression. Treatment modes and results].

Authors:  J C Kiwit; A Zeiner
Journal:  Urologe A       Date:  2003-12       Impact factor: 0.639

Review 2.  [Diagnosis of neurogenic bladder dysfunction].

Authors:  A Kaufmann; I Kurze
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

3.  Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction.

Authors:  Cheng-Ling Lee; Jia-Fong Jhang; Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2022-01-02       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.